{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:27:43Z","timestamp":1790832463205,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gain of chromosome 1q (+1q) is commonly identified in multiple myeloma and has been associated with inferior outcomes. However, the prognostic implication of +1q has not been evaluated in the setting of standard triplet regimens. We retrospectively analyzed 201 consecutive patients with newly diagnosed myeloma who received induction with lenalidomide, bortezomib, and dexamethasone (RVD) and were tested for +1q at diagnosis by fluorescent in-situ hybridization. Patients with +1q (<jats:italic>n<\/jats:italic>\u2009=\u200994), compared to those without +1q (<jats:italic>n<\/jats:italic>\u2009=\u2009107), had shorter median progression-free survival (PFS) (41.9 months vs 65.1 months, <jats:italic>p<\/jats:italic>\u2009=\u20090.002, HR\u2009=\u20091.90) and overall survival (median not reached (NR) for either arm, <jats:italic>p<\/jats:italic>\u2009=\u20090.003, HR 2.69). In subgroup analyses, patients with co-occurring +1q and t(4;14), t(14;16) or del(17p) or with 4 or more copies of 1q had significantly worse PFS (25.1 months and 34.6 months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 and <jats:italic>p<\/jats:italic>\u2009=\u20090.0063, respectively), whereas patients with three copies and no other high-risk cytogenetic abnormalities had no significant difference in PFS. These data suggest that when treated with RVD induction, patients with +1q should be considered at very high risk for early progression in multiple myeloma when \u22654 copies are detected or in the context of other high-risk cytogenetic abnormalities.<\/jats:p>","DOI":"10.1038\/s41408-019-0254-0","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T18:02:52Z","timestamp":1574704972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":149,"title":["Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5860-2640","authenticated-orcid":false,"given":"Timothy M.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9810-3566","authenticated-orcid":false,"given":"Benjamin G.","family":"Barwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard T.","family":"Heffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4816-1607","authenticated-orcid":false,"given":"Craig C.","family":"Hofmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav V.","family":"Dhodapkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas A.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Jaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subir","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H.","family":"Boise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5687-6429","authenticated-orcid":false,"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"key":"254_CR1","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Revised International staging system for multiple myeloma: a report from International Myeloma Working Group. J. Clin. Oncol. 33, 2863\u20132869 (2015).","journal-title":"J. Clin. Oncol."},{"key":"254_CR2","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","volume":"108","author":"I Hanamura","year":"2006","unstructured":"Hanamura, I. et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 108, 1724\u20131732 (2006).","journal-title":"Blood."},{"key":"254_CR3","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","volume":"116","author":"BA Walker","year":"2010","unstructured":"Walker, B. A. et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 116, e56\u2013e65 (2010).","journal-title":"Blood."},{"key":"254_CR4","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/JCO.2011.36.5726","volume":"30","author":"H Avet-Loiseau","year":"2012","unstructured":"Avet-Loiseau, H. et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J. Clin. Oncol. 30, 1949\u20131952 (2012).","journal-title":"J. Clin. Oncol."},{"key":"254_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/leu.2011.204","volume":"26","author":"KD Boyd","year":"2012","unstructured":"Boyd, K. D. et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 26, 349\u2013355 (2012).","journal-title":"Leukemia."},{"key":"254_CR6","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.bbmt.2009.11.025","volume":"16","author":"P Nemec","year":"2010","unstructured":"Nemec, P. et al. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol. Blood Marrow Transplant 16, 548\u2013554 (2010).","journal-title":"Biol. Blood Marrow Transplant"},{"key":"254_CR7","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","volume":"20","author":"R Fonseca","year":"2006","unstructured":"Fonseca, R. et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 20, 2034\u20132040 (2006).","journal-title":"Leukemia."},{"key":"254_CR8","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1200\/JCO.2008.20.6136","volume":"27","author":"H Avet-Loiseau","year":"2009","unstructured":"Avet-Loiseau, H. et al. Prognostic significance of copy-number alterations in multiple myeloma. J. Clin. Oncol. 27, 4585\u20134590 (2009).","journal-title":"J. Clin. Oncol."},{"key":"254_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.clml.2012.11.012","volume":"13","author":"J Smetana","year":"2013","unstructured":"Smetana, J. et al. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib. Clin. Lymphoma Myeloma Leuk. 13, 123\u2013130 (2013).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"254_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2013.088211","volume":"99","author":"G An","year":"2014","unstructured":"An, G. et al. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica. 99, 353\u2013359 (2014).","journal-title":"Haematologica."},{"key":"254_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.leukres.2010.05.002","volume":"35","author":"H Chang","year":"2011","unstructured":"Chang, H. et al. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains. Leuk. Res. 35, 95\u201398 (2011).","journal-title":"Leuk. Res."},{"key":"254_CR12","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1080\/10428194.2016.1260126","volume":"58","author":"GL Shah","year":"2017","unstructured":"Shah, G. L. et al. Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leuk. Lymphoma. 58, 1823\u20131831 (2017).","journal-title":"Leuk. Lymphoma."},{"key":"254_CR13","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/leu.2010.175","volume":"24","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos, M. A. et al. Treatment of patients with relapsed\/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 24, 1769\u20131778 (2010).","journal-title":"Leukemia."},{"key":"254_CR14","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1182\/blood.V91.5.1732","volume":"91","author":"JR Sawyer","year":"1998","unstructured":"Sawyer, J. R., Tricot, G., Mattox, S., Jagannath, S. & Barlogie, B. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood. 91, 1732\u20131741 (1998).","journal-title":"Blood."},{"key":"254_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/bmt.2009.107","volume":"45","author":"H Chang","year":"2010","unstructured":"Chang, H. et al. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant. 45, 117\u2013121 (2010).","journal-title":"Bone Marrow Transplant."},{"key":"254_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/leu.2013.225","volume":"28","author":"B Hebraud","year":"2014","unstructured":"Hebraud, B. et al. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia. 28, 675\u2013679 (2014).","journal-title":"Leukemia."},{"key":"254_CR17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3389\/fimmu.2019.01121","volume":"10","author":"BG Barwick","year":"2019","unstructured":"Barwick, B. G., Gupta, V. A., Vertino, P. M. & Boise, L. H. Cell of origin and genetic alterations in the pathogenesis of multiple myeloma. Front Immunol. 10, 1121 (2019).","journal-title":"Front Immunol."},{"key":"254_CR18","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy","year":"2007","unstructured":"Shaughnessy, J. D. et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 109, 2276\u20132284 (2007).","journal-title":"Blood."},{"issue":"Suppl 1","key":"254_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/10245330512331390140","volume":"10","author":"J Shaughnessy","year":"2005","unstructured":"Shaughnessy, J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology. 10(Suppl 1), 117\u2013126 (2005).","journal-title":"Hematology."},{"key":"254_CR20","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1182\/blood-2018-02-832576","volume":"132","author":"PJ Teoh","year":"2018","unstructured":"Teoh, P. J. et al. Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. Blood. 132, 1304\u20131317 (2018).","journal-title":"Blood."},{"key":"254_CR21","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/gcc.2","volume":"57","author":"AA Samo","year":"2018","unstructured":"Samo, A. A. et al. MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy. Genes Chromosomes Cancer 57, 420\u2013429 (2018).","journal-title":"Genes Chromosomes Cancer"},{"key":"254_CR22","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal, M. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N. Engl. J. Med. 376, 1311\u20131320 (2017).","journal-title":"N. Engl. J. Med."},{"key":"254_CR23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie, B. G. M. et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. The Lancet. 389, 519\u2013527 (2017).","journal-title":"The Lancet."},{"key":"254_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09555-6","volume":"10","author":"BG Barwick","year":"2019","unstructured":"Barwick, B. G. et al. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nat. Commun. 10, 1911 (2019).","journal-title":"Nat. Commun."},{"key":"254_CR25","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1182\/blood-2012-09-451872","volume":"121","author":"AK Stewart","year":"2013","unstructured":"Stewart, A. K. et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood. 121, 1517\u20131523 (2013).","journal-title":"Blood."},{"key":"254_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","volume":"33","author":"BA Walker","year":"2019","unstructured":"Walker, B. A. et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 33, 159\u2013170 (2019).","journal-title":"Leukemia."},{"key":"254_CR27","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/leu.2013.335","volume":"28","author":"AK Nooka","year":"2014","unstructured":"Nooka, A. K. et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 28, 690\u2013693 (2014).","journal-title":"Leukemia."},{"key":"254_CR28","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot, A. et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 132, 2456\u20132464 (2018).","journal-title":"Blood."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0254-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0254-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0254-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T16:15:33Z","timestamp":1671207333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0254-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["254"],"URL":"https:\/\/doi.org\/10.1038\/s41408-019-0254-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"3 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.T.H. declares research funding from Pharmacyclics, Genentech, Kite Pharma, and ADC Therapeutics. C.C.H. declares research funding from Bristol-Myers Squibb and membership on an advisory committee for Celgene, Oncopeptides, Adaptive Biotechnologies, and Janssen. M.V.D. declares membership in advisory boards for Amgen, Janssen, Roche, Celgene, Kite, and Lava Therapeutics. L.H.B. declares consultancy for Abbvie and Genentech, and honoraria and research funding from AstraZeneca. S.L. declares research funding from Amgen. A.K.N. declares consultancy and\/or membership on an advisory committee for Spectrum Pharmaceuticals, Bristol-Myers Squibb, Adaptive Biotechnologies, Amgen, Celgene, Takeda, GlaxoSmithKline, and Janssen. J.L.K. declares consultancy for Celgene, Takeda, Amgen Janssen, and Sanofi. The remaining authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"94"}}